Completed NA Interventional NCT00246649
Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia
Pilot Study of Ex Vivo Expansion of Mafosfamide-Purged CD34-Positive Cells for Autologous Peripheral Blood Stem Cell or Bone Marrow Transplantation in Patients With Acute Leukemia
Sponsor: National Institutes of Health (NIH)
Conditions
ALL (High Risk) AML
Interventions
Ex vivo expansion of mafosfamide purged marrow or mobilized stem cells with growth factors (rhSCF and rhTPO)
Updated 1 time since 2017 Last updated: Oct 27, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A NA clinical study on ALL (High Risk) and AML, this trial is completed. The trial is conducted by National Institutes of Health (NIH) and has accumulated 1 data snapshot since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Completed — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- National Institutes of Health (NIH)
- Sidney Kimmel Comprehensive Cancer Center
Data source: Sidney Kimmel Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .